Herpesvirus entry mediator
Herpesvirus entry mediator (HVEM), also known as TNFRSF14 (tumor necrosis factor receptor superfamily member 14), is a protein that in humans is encoded by the TNFRSF14 gene. It is a member of the tumor necrosis factor receptor superfamily and plays a key role in the entry of herpesvirus into cells.
Structure[edit | edit source]
The HVEM protein is a type I membrane protein that is expressed in many immune cells, including T cells, B cells, and monocytes. It consists of an extracellular domain containing four cysteine-rich repeats, a transmembrane domain, and a cytoplasmic domain that contains a death domain motif.
Function[edit | edit source]
HVEM acts as a receptor for herpes simplex virus (HSV) and pseudorabies virus (PRV), facilitating their entry into cells. It interacts with the viral glycoprotein D (gD), which is present on the surface of the virus. This interaction triggers a series of events that lead to the fusion of the viral envelope with the cell membrane, allowing the virus to enter the cell.
In addition to its role in viral entry, HVEM also plays a role in immune regulation. It can interact with several ligands, including LIGHT and BTLA, to modulate immune responses. For example, the interaction between HVEM and BTLA can inhibit T cell activation, providing a mechanism for immune tolerance.
Clinical significance[edit | edit source]
Mutations in the TNFRSF14 gene can lead to a variety of immune disorders. For example, loss-of-function mutations have been associated with an increased risk of autoimmune diseases, such as rheumatoid arthritis and lupus. On the other hand, gain-of-function mutations can lead to the development of certain types of cancer, including non-Hodgkin lymphoma and cutaneous T cell lymphoma.
Research[edit | edit source]
Research is ongoing to develop drugs that can block the interaction between HVEM and its ligands, with the aim of preventing herpesvirus infection or modulating immune responses. Several small molecule inhibitors and monoclonal antibodies are currently in preclinical or early clinical development.
See also[edit | edit source]
References[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
